MedPath

Ambrisentan

Generic Name
Ambrisentan
Brand Names
Letairis, Volibris, Ambrisentan Mylan
Drug Type
Small Molecule
Chemical Formula
C22H22N2O4
CAS Number
177036-94-1
Unique Ingredient Identifier
HW6NV07QEC

Overview

Ambrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening. In addition, it is approved in the United States for use in combination with tadalafil to reduce the risks of disease progression, hospitalization and to improve exercise ability. Studies establishing the efficacy of Ambrisentan included patients with both idiopathic or heritable pulmonary arterial hypertension and those with pulmonary arterial hypertension associated with connective tissue diseases. Patients studied displayed symptoms and etiologies predominantly of WHO Functional Class II-III. As an endothelin receptor antagonist, Ambrisentan prevents endogenous endothelin peptide from constricting the muscles in blood vessels, allowing them to relax and permit a reduction in blood pressure.

Background

Ambrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening. In addition, it is approved in the United States for use in combination with tadalafil to reduce the risks of disease progression, hospitalization and to improve exercise ability. Studies establishing the efficacy of Ambrisentan included patients with both idiopathic or heritable pulmonary arterial hypertension and those with pulmonary arterial hypertension associated with connective tissue diseases. Patients studied displayed symptoms and etiologies predominantly of WHO Functional Class II-III. As an endothelin receptor antagonist, Ambrisentan prevents endogenous endothelin peptide from constricting the muscles in blood vessels, allowing them to relax and permit a reduction in blood pressure.

Indication

用于治疗肺动脉高血压(PAH)。

Associated Conditions

  • Pulmonary arterial hypertension WHO functional class I

FDA Approved Products

AMBRISENTAN
Manufacturer:Sigmapharm Laboratories, LLC
Route:ORAL
Strength:5 mg in 1 1
Approved: 2023/01/10
NDC:42794-051
Ambrisentan
Manufacturer:Mylan Pharmaceuticals Inc.
Route:ORAL
Strength:10 mg in 1 1
Approved: 2019/08/15
NDC:0378-4271
Letairis
Manufacturer:Gilead Sciences, Inc
Route:ORAL
Strength:5 mg in 1 1
Approved: 2020/12/17
NDC:61958-0801
Ambrisentan
Manufacturer:Exelan Pharmaceuticals, Inc.
Route:ORAL
Strength:5 mg in 1 1
Approved: 2020/07/22
NDC:76282-684
Ambrisentan
Manufacturer:Zydus Pharmaceuticals USA Inc.
Route:ORAL
Strength:10 mg in 1 1
Approved: 2023/03/16
NDC:70710-1180

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath